{"id":42994,"date":"2018-12-18T16:10:32","date_gmt":"2018-12-18T14:10:32","guid":{"rendered":"https:\/\/blog.cofb.cat\/?p=42994"},"modified":"2018-12-18T16:10:32","modified_gmt":"2018-12-18T14:10:32","slug":"quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/","title":{"rendered":"Quins aspectes cal tenir en compte en la rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria?"},"content":{"rendered":"<p>El passat 26 de novembre el COFB va acollir la sessi\u00f3 <strong>&#8220;Rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria, aspectes a tenir en compte&#8221;<\/strong>, que va anar a c\u00e0rrec d&#8217;Ariadna Crusellas, farmac\u00e8utica comunit\u00e0ria, formulista, m\u00e0ster d&#8217;expert en f\u00f3rmules magistrals de la Universitat San Jorge de Saragossa i presidenta d&#8217;Aprofarm i Josep Pedrals, farmac\u00e8utic comunitari, formulista i vicepresident d&#8217;Aprofarm. El moderador va ser Francesc Llamb\u00ed, vocal del COFB i professor associat de la Unitat de Tecnologia Farmac\u00e8utica de la Facultat de Farm\u00e0cia de la UB.<\/p>\n<h1><span style=\"color: #008080;\"><strong>La formulaci\u00f3 magistral, tasca inherent a l&#8217;activitat professional de l&#8217;oficina de farm\u00e0cia<\/strong><\/span><\/h1>\n<p>La<strong> formulaci\u00f3 magistral<\/strong> forma part de &#8220;<strong>l&#8217;ess\u00e8ncia&#8221; de l&#8217;activitat professional de l&#8217;oficina de farm\u00e0cia<\/strong> i els farmac\u00e8utics s\u00f3n els &#8220;t\u00e8cnics-garants-especialistes&#8221; dels medicaments. Durant la sessi\u00f3, es va posar de manifest que tot el que un dia eren <strong>tractaments individualitzats<\/strong> o <strong>f\u00f3rmules magistrals<\/strong> ara s\u00f3n tot (o gaireb\u00e9 tot) <strong>especialitats<\/strong> (medicaments comercialitzats).<\/p>\n<p>Malgrat que les <strong>especialitats<\/strong> han comportat progr\u00e9s, efic\u00e0cia i universalitat a la medicina, sempre hi ha hagut i hi haur\u00e0 lloc per als tractaments individualitzats, ja que:<\/p>\n<ul>\n<li>els individus tenen diferent <strong>edat<\/strong>, <strong>pes<\/strong> i no tots reaccionen de la mateixa manera<\/li>\n<li>la ind\u00fastria no pot<strong> rendibilitzar tractaments minoritaris<\/strong><\/li>\n<\/ul>\n<figure id=\"attachment_43169\" aria-describedby=\"caption-attachment-43169\" style=\"width: 620px\" class=\"wp-caption aligncenter\"><a href=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/12\/cofb.formulaci\u00f3-magistral.181126-10.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-43169 size-large\" title=\"Els farmac\u00e8utics comunitaris i formulistes Ariadna Crusellas i Josep Pedrals, presidenta i vicepresident d'Aprofarm, durant la sessi\u00f3.\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/12\/cofb.formulaci\u00f3-magistral.181126-10-1024x683.jpg\" alt=\"Els farmac\u00e8utics comunitaris i formulistes Ariadna Crusellas i Josep Pedrals, presidenta i vicepresident d'Aprofarm, durant la sessi\u00f3.\" width=\"620\" height=\"414\" \/><\/a><figcaption id=\"caption-attachment-43169\" class=\"wp-caption-text\">Els farmac\u00e8utics comunitaris i formulistes Ariadna Crusellas i Josep Pedrals, presidenta i vicepresident d&#8217;Aprofarm, durant la sessi\u00f3.<\/figcaption><\/figure>\n<p>Per aquest motiu, durant l&#8217;acte es va incidir en el fet que la <strong>formulaci\u00f3 magistral \u00e9s una \u00e0rea que en funci\u00f3 de com es gestioni pot tenir una rendibilitat<\/strong>, per exemple, si tenim en compte aspectes com l&#8217;<strong>optimitzaci\u00f3 de recursos<\/strong> o l&#8217;<strong>an\u00e0lisi de costos<\/strong>.<\/p>\n<h1><strong><span style=\"color: #008080;\">An\u00e0lisi de costos dels laboratoris<\/span><\/strong><\/h1>\n<p><strong>Quines inversions i despeses m\u00ednimes tenen els laboratoris?<\/strong> Per donar resposta a aquesta q\u00fcesti\u00f3 es va posar de manifest quines <strong>inversions m\u00ednimes<\/strong> requereixen els laboratoris i quines <strong>despeses m\u00ednimes<\/strong> comporten.<\/p>\n<div class=\"box success\"><\/p>\n<p>La <strong>gesti\u00f3 del laboratori<\/strong> \u00e9s prou important i \u00fatil per sustentar la tasca de la <strong>formulaci\u00f3 magistral\u00a0<\/strong>i permet valorar amb <strong>par\u00e0metres propis<\/strong> quina \u00e9s la <strong>rendibilitat de la formulaci\u00f3 magistral<\/strong>.<\/p>\n<p><\/div>\n<p>Entre les<strong> inversions<\/strong> es van remarcar l&#8217;<strong>espai<\/strong>, l&#8217;<strong>utillatge<\/strong>, els <strong>aparells<\/strong>, els <strong>costos d&#8217;inventari inicial<\/strong>, el<strong> material inform\u00e0tic<\/strong> i d&#8217;<strong>oficina<\/strong>, els <strong>envasos<\/strong> i el <strong>material d&#8217;embalatge<\/strong>. Com a <strong>despeses m\u00ednimes<\/strong> es van destacar les de personal, llum i climatitzaci\u00f3, aigua i tel\u00e8fon, espai, costos directes de fabricaci\u00f3, gesti\u00f3 de residus&#8230;<\/p>\n<h1><strong><span style=\"color: #008080;\">F\u00f3rmules magistrals\u00a0<\/span><\/strong><\/h1>\n<p>Tot seguit, es van repassar els aspectes a tenir en compte de les <strong>f\u00f3rmules magistrals<\/strong>. En concret, el <strong>preu dels principis actius<\/strong> (pol\u00edtica de compres, negociaci\u00f3 amb els prove\u00efdors de mat\u00e8ries primeres i envasos, c\u00e0lcul de les necessitats per a la nostra realitat&#8230;), preu dels <strong>excipients<\/strong>, preu dels <strong>utillatges\/aparells<\/strong>, preu de l&#8217;<strong>elaborador<\/strong> (temps que requereix cada f\u00f3rmula, cost de fer un control espec\u00edfic de la f\u00f3rmula, cost del personal que l&#8217;elabora&#8230;), preu de l&#8217;<strong>env\u00e0s<\/strong> (elecci\u00f3 del millor env\u00e0s i el millor preu, estoc \u00f2ptim per la nostra tasca, cost de l&#8217;estoc immobilitzat al laboratori&#8230;), preu de l&#8217;<strong>etiqueta<\/strong>, preu de la <strong>documentaci\u00f3<\/strong> (temps dedicat a generar informaci\u00f3 i a tenir-la actualitzada&#8230;) i preu de la <strong>infraestructura<\/strong> (cost fix, espai ocupat pel nostre laboratori&#8230;).<\/p>\n<p>La presidenta i el vicepresident d&#8217;Aprofarm van recalcar que &#8220;la <strong>formulaci\u00f3 magistral \u00e9s l&#8217;\u00fanica cosa exclusivament de l&#8217;oficina de farm\u00e0cia que no es pot trobar enlloc m\u00e9s<\/strong>, la qual cosa suposa una <strong>oportunitat<\/strong> per <strong>treballar la formulaci\u00f3 magistral<\/strong> amb la <strong>dispensaci\u00f3 activa<\/strong> i atendre directament la necessitat del client que demana una formulaci\u00f3 magistral i donar-li un servei&#8221;.<\/p>\n<h1><strong><span style=\"color: #008080;\">Reflexions sobre la jornada<\/span><\/strong><\/h1>\n<p>Francesc Llamb\u00ed,\u00a0vocal del COFB i professor associat de la Unitat de Tecnologia Farmac\u00e8utica de la Facultat de Farm\u00e0cia de la UB, va destacar que <strong>durant la sessi\u00f3 es van repassar<\/strong> &#8220;una<strong> s\u00e8rie de punts<\/strong> que, certament, tothom que tingui un laboratori de formulaci\u00f3, peri\u00f2dicament, ha d\u2019<strong>incidir-hi<\/strong>&#8221; i que considera <strong>&#8220;molt \u00fatils pels farmac\u00e8utics&#8221;<\/strong>.<\/p>\n<figure id=\"attachment_42999\" aria-describedby=\"caption-attachment-42999\" style=\"width: 620px\" class=\"wp-caption aligncenter\"><a href=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/12\/cofb.formulaci\u00f3-magsitral.181126-01.jpg\"><img decoding=\"async\" class=\"wp-image-42999 size-large\" title=\"D'esquerra a dreta:\u00a0 Josep Pedrals, farmac\u00e8utic comunitari, formulista i vicepresident d'Aprofarm;Ariadna Crusellas, farmac\u00e8utica comunit\u00e0ria, formulista i presidenta d'Aprofarm i Francesc Llamb\u00ed, vocal del COFB i professor associat de la Unitat de Tecnologia Farmac\u00e8utica de la Facultat de Farm\u00e0cia de la UB.\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/12\/cofb.formulaci\u00f3-magsitral.181126-01-1024x683.jpg\" alt=\"D'esquerra a dreta:\u00a0 Josep Pedrals, farmac\u00e8utic comunitari, formulista i vicepresident d'Aprofarm;Ariadna Crusellas, farmac\u00e8utica comunit\u00e0ria, formulista i presidenta d'Aprofarm i Francesc Llamb\u00ed, vocal del COFB i professor associat de la Unitat de Tecnologia Farmac\u00e8utica de la Facultat de Farm\u00e0cia de la UB.\" width=\"620\" height=\"414\" \/><\/a><figcaption id=\"caption-attachment-42999\" class=\"wp-caption-text\">D&#8217;esquerra a dreta:\u00a0 Josep Pedrals, farmac\u00e8utic comunitari, formulista i vicepresident d&#8217;Aprofarm;Ariadna Crusellas, farmac\u00e8utica comunit\u00e0ria, formulista i presidenta d&#8217;Aprofarm i Francesc Llamb\u00ed, vocal del COFB i professor associat de la Unitat de Tecnologia Farmac\u00e8utica de la Facultat de Farm\u00e0cia de la UB.<\/figcaption><\/figure>\n<p>&#8220;El <strong>funcionament de cada laboratori \u00e9s diferent<\/strong> i <strong>cadasc\u00fa ha d&#8217;aplicar les reflexions que hagi fet<\/strong>. Respecte incrementar el nombre de formulacions, en aquest punt influeixen <strong>decisions pr\u00f2pies de cadasc\u00fa a l&#8217;oficina de farm\u00e0cia<\/strong> i tamb\u00e9 <strong>temes m\u00e9s generals <\/strong>que hem de saber tractar&#8221;, va concloure.<\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: right;\"><strong>Activitat organitzada conjuntament amb:<\/strong><\/p>\n<p style=\"text-align: right;\"><a href=\"http:\/\/www.fefac.cat\/\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" class=\" wp-image-43022 alignright\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/12\/FEFAC-1024x401.jpg\" alt=\"\" width=\"169\" height=\"66\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p style=\"text-align: right;\"><strong>Amb la col\u00b7laboraci\u00f3 de:<\/strong><\/p>\n<p><a href=\"http:\/\/aprofarm.com\/\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-43021 alignright\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2018\/12\/aprofarm-1024x230.jpg\" alt=\"\" width=\"214\" height=\"48\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Altres publicacions d&#8217;inter\u00e8s:<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/blog.cofb.cat\/formules-magistrals-per-la-mucosa-oral-formacio-amb-especial-significacio-dins-la-farmacia\/\" target=\"_blank\" rel=\"noopener\">F\u00f3rmules magistrals per la mucosa oral: formaci\u00f3 amb especial significaci\u00f3 dins la farm\u00e0cia (Mar\u00e7 2018)<\/a><\/li>\n<li><a href=\"https:\/\/blog.cofb.cat\/ix-forum-aprofarm-20-anys-al-costat-del-formulador\/\" target=\"_blank\" rel=\"noopener\">IX F\u00f2rum Aprofarm: &#8220;20 anys al costat del formulador&#8221; (Juny 2016)<\/a><\/li>\n<li><a href=\"https:\/\/blog.cofb.cat\/mes-col%C2%B7laboracio-per-implementar-la-formulacio-magistral-una-tendencia-a-lalca\/#prettyPhoto\" target=\"_blank\" rel=\"noopener\">M\u00e9s col\u00b7laboraci\u00f3 per implementar la formulaci\u00f3 magistral, una tend\u00e8ncia a l&#8217;al\u00e7a (Juny 2014)<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>El passat 26 de novembre el COFB va acollir la sessi\u00f3 &#8220;Rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria, aspectes a tenir en compte&#8221;, que va anar a c\u00e0rrec d&#8217;Ariadna Crusellas, farmac\u00e8utica comunit\u00e0ria, formulista, m\u00e0ster d&#8217;expert en f\u00f3rmules magistrals de la Universitat San Jorge de Saragossa i presidenta d&#8217;Aprofarm [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":43169,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[18,19,3367,3368,53,24,69,3369,154,650,3370,3371,2163,3311,45,76,3372],"class_list":["post-42994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-especialitats","tag-excipients","tag-farmaceutics","tag-farmaceutics-comunitaris","tag-farmacia-comunitaria","tag-formula-magistral","tag-formulacio","tag-formulacio-magistral","tag-formulacio-personalitzada","tag-formules","tag-laboratori-clinic","tag-laboratoris","tag-medicaments","tag-oficina-de-farmacia","tag-rendibilitat"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Quins aspectes cal tenir en compte en la rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria? - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"description\" content=\"El passat 26 de novembre el COFB va acollir la sessi\u00f3 &quot;Rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria, aspectes a tenir en compte&quot;, que va anar a c\u00e0rrec d&#039;Ariadna Crusellas, Josep Pedrals i Francesc Llamb\u00ed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quins aspectes cal tenir en compte en la rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"El passat 26 de novembre el COFB va acollir la sessi\u00f3 &quot;Rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria, aspectes a tenir en compte&quot;, que va anar a c\u00e0rrec d&#039;Ariadna Crusellas, Josep Pedrals i Francesc Llamb\u00ed.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-18T14:10:32+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Quins aspectes cal tenir en compte en la rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria?\",\"datePublished\":\"2018-12-18T14:10:32+00:00\",\"dateModified\":\"2018-12-18T14:10:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/\"},\"wordCount\":888,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"especialitats\",\"excipients\",\"farmac\u00e8utics\",\"farmac\u00e8utics comunitaris\",\"farm\u00e0cia comunit\u00e0ria\",\"f\u00f3rmula magistral\",\"formulaci\u00f3\",\"Formulaci\u00f3 magistral\",\"formulaci\u00f3 personalitzada\",\"f\u00f3rmules\",\"Laboratori cl\u00ednic\",\"laboratoris\",\"medicaments\",\"Oficina de farm\u00e0cia\",\"rendibilitat\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/\",\"name\":\"Quins aspectes cal tenir en compte en la rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria? - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2018-12-18T14:10:32+00:00\",\"dateModified\":\"2018-12-18T14:10:32+00:00\",\"description\":\"El passat 26 de novembre el COFB va acollir la sessi\u00f3 \\\"Rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria, aspectes a tenir en compte\\\", que va anar a c\u00e0rrec d'Ariadna Crusellas, Josep Pedrals i Francesc Llamb\u00ed.\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quins aspectes cal tenir en compte en la rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quins aspectes cal tenir en compte en la rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"El passat 26 de novembre el COFB va acollir la sessi\u00f3 \"Rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria, aspectes a tenir en compte\", que va anar a c\u00e0rrec d'Ariadna Crusellas, Josep Pedrals i Francesc Llamb\u00ed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/","og_locale":"ca_ES","og_type":"article","og_title":"Quins aspectes cal tenir en compte en la rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"El passat 26 de novembre el COFB va acollir la sessi\u00f3 \"Rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria, aspectes a tenir en compte\", que va anar a c\u00e0rrec d'Ariadna Crusellas, Josep Pedrals i Francesc Llamb\u00ed.","og_url":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2018-12-18T14:10:32+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"4 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Quins aspectes cal tenir en compte en la rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria?","datePublished":"2018-12-18T14:10:32+00:00","dateModified":"2018-12-18T14:10:32+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/"},"wordCount":888,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","keywords":["COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","especialitats","excipients","farmac\u00e8utics","farmac\u00e8utics comunitaris","farm\u00e0cia comunit\u00e0ria","f\u00f3rmula magistral","formulaci\u00f3","Formulaci\u00f3 magistral","formulaci\u00f3 personalitzada","f\u00f3rmules","Laboratori cl\u00ednic","laboratoris","medicaments","Oficina de farm\u00e0cia","rendibilitat"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/","url":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/","name":"Quins aspectes cal tenir en compte en la rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria? - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","datePublished":"2018-12-18T14:10:32+00:00","dateModified":"2018-12-18T14:10:32+00:00","description":"El passat 26 de novembre el COFB va acollir la sessi\u00f3 \"Rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria, aspectes a tenir en compte\", que va anar a c\u00e0rrec d'Ariadna Crusellas, Josep Pedrals i Francesc Llamb\u00ed.","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2018\/12\/18\/quins-aspectes-cal-tenir-compte-rendibilitat-formulacio-magistral-farmacia-comunitaria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Quins aspectes cal tenir en compte en la rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria?"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"El passat 26 de novembre el COFB va acollir la sessi\u00f3 &#8220;Rendibilitat de la formulaci\u00f3 magistral a la farm\u00e0cia comunit\u00e0ria, aspectes a tenir en compte&#8221;, que va anar a c\u00e0rrec d&#8217;Ariadna Crusellas, farmac\u00e8utica comunit\u00e0ria, formulista, m\u00e0ster d&#8217;expert en f\u00f3rmules magistrals de la Universitat San Jorge de Saragossa i presidenta d&#8217;Aprofarm [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/42994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=42994"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/42994\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=42994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=42994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=42994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}